KB16A
Immuno-Oncology
DiscoveryActive
Key Facts
About KBio
KBio is pioneering a plant-based manufacturing platform, RP3, designed to produce monoclonal antibodies and other biologics more rapidly, scalably, and sustainably than conventional CHO cell systems. The company has a preclinical pipeline targeting high-demand areas like invasive fungal infections and immuno-oncology, with programs such as KB14A for aspergillosis and candida. As a private, pre-revenue biotech, KBio's strategy is built on validating its platform through internal pipeline advancement and strategic partnerships to disrupt the biologics production landscape.
View full company profileTherapeutic Areas
Other Immuno-Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| PD-1/PD-L1 Inhibitor Binding Assay Kit | Aurora Biolabs | Commercial |
| CTLA-4/B7-1 Inhibitor Screening Kit | Aurora Biolabs | Commercial |
| OX40 & PD-1 Assay | Aurora Biolabs | Commercial |
| HPK1 inhibitor | Acellera | Pre-clinical |
| SKP2-CKS1 PPI Inhibitor | Iktos | Hit-to-Lead |
| PD-1 Expression Inhibitor | BCN Biosciences | Preclinical |
| CCR8 ADC | Integral Molecular | Preclinical |
| NeoSight Neoantigen Detection | ReproCELL | Research/Clinical |
| EMUNKITUG (HFB200301) | HiFiBiO Therapeutics | Phase 1 |
| HFB200603 | HiFiBiO Therapeutics | Phase 1 |
| Undisclosed Multispecific Therapeutics | ModeX Therapeutics | Pre-clinical |
| Undisclosed | Onco3R Therapeutics | Preclinical |